178 related articles for article (PubMed ID: 32333922)
1. R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder
Witkin JM; Kranzler J; Kaniecki K; Popik P; Smith JL; Hashimoto K; Sporn J
Pharmacol Biochem Behav; 2020 Jul; 194():172927. PubMed ID: 32333922
[TBL] [Abstract][Full Text] [Related]
2. Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.
Hillhouse TM; Porter JH; Negus SS
Psychopharmacology (Berl); 2014 Jul; 231(13):2705-16. PubMed ID: 24522331
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Bhateja P; Singh TG; Singh N
Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
[TBL] [Abstract][Full Text] [Related]
4. Higher anhedonia during withdrawal from initial opioid exposure is protective against subsequent opioid self-administration in rats.
Swain Y; Muelken P; Skansberg A; Lanzdorf D; Haave Z; LeSage MG; Gewirtz JC; Harris AC
Psychopharmacology (Berl); 2020 Aug; 237(8):2279-2291. PubMed ID: 32388620
[TBL] [Abstract][Full Text] [Related]
5. Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice.
Zhang G; Wu X; Zhang YM; Liu H; Jiang Q; Pang G; Tao X; Dong L; Stackman RW
Neuropharmacology; 2016 Feb; 101():246-54. PubMed ID: 26432939
[TBL] [Abstract][Full Text] [Related]
6. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice.
de Cordé A; Krząścik P; Wolińska R; Kleczkowska P; Filip M; Bujalska-Zadrożny M
Behav Pharmacol; 2018 Aug; 29(5):393-399. PubMed ID: 29462108
[TBL] [Abstract][Full Text] [Related]
7. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
Lofwall MR; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
[TBL] [Abstract][Full Text] [Related]
8. Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
Cavun S; Göktalay G; Millington WR
J Pharmacol Exp Ther; 2005 Nov; 315(2):949-58. PubMed ID: 16079299
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Stinus L; Cador M; Zorrilla EP; Koob GF
Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
[TBL] [Abstract][Full Text] [Related]
10. Oxytocin mediates the inhibitory action of acute lithium on the morphine dependence in rats.
You ZD; Li JH; Song CY; Lu CL; He C
Neurosci Res; 2001 Oct; 41(2):143-50. PubMed ID: 11591442
[TBL] [Abstract][Full Text] [Related]
11. Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats.
Ayoub SM; Smoum R; Farag M; Atwal H; Collins SA; Rock EM; Limebeer CL; Piscitelli F; Iannotti FA; Lichtman AH; Leri F; Di Marzo V; Mechoulam R; Parker LA
Psychopharmacology (Berl); 2020 Sep; 237(9):2753-2765. PubMed ID: 32556401
[TBL] [Abstract][Full Text] [Related]
12. Fecal microbiota transplantation and antibiotic treatment attenuate naloxone-precipitated opioid withdrawal in morphine-dependent mice.
Thomaz AC; Iyer V; Woodward TJ; Hohmann AG
Exp Neurol; 2021 Sep; 343():113787. PubMed ID: 34153321
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide trefoil factor 3 attenuates naloxone-precipitated withdrawal in morphine-dependent mice.
Wu P; Shi HS; Luo YX; Zhang RX; Li JL; Shi J; Lu L; Zhu WL
Psychopharmacology (Berl); 2014 Dec; 231(24):4659-68. PubMed ID: 24825609
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.
Snyder GL; Li P; Martin T; Zhang L; Yao W; Zheng H; Maguire DR; Gerak LR; Vanover KE; France CP; Davis R
Psychopharmacology (Berl); 2024 Jul; 241(7):1477-1490. PubMed ID: 38710856
[TBL] [Abstract][Full Text] [Related]
15. Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague-Dawley rats.
Petrie GN; Wills KL; Piscitelli F; Smoum R; Limebeer CL; Rock EM; Humphrey AE; Sheppard-Perkins M; Lichtman AH; Mechoulam R; Di Marzo V; Parker LA
Psychopharmacology (Berl); 2019 Sep; 236(9):2623-2633. PubMed ID: 30993360
[TBL] [Abstract][Full Text] [Related]
16. Effects of repeated morphine on intracranial self-stimulation in male rats in the absence or presence of a noxious pain stimulus.
Miller LL; Altarifi AA; Negus SS
Exp Clin Psychopharmacol; 2015 Oct; 23(5):405-14. PubMed ID: 26375515
[TBL] [Abstract][Full Text] [Related]
17. Some determinants of morphine effects on intracranial self-stimulation in rats: dose, pretreatment time, repeated treatment, and rate dependence.
Altarifi AA; Negus SS
Behav Pharmacol; 2011 Oct; 22(7):663-73. PubMed ID: 21921839
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous withdrawal in intermittent morphine administration in rats and mice: effect of clonidine coadministration and sex-related differences.
Allahverdiyev O; Türkmen AZ; Nurten A; Sehirli I; Enginar N
Turk J Med Sci; 2015; 45(6):1380-9. PubMed ID: 26775398
[TBL] [Abstract][Full Text] [Related]
19. Brain reward deficits accompany naloxone-precipitated withdrawal from acute opioid dependence.
Liu J; Schulteis G
Pharmacol Biochem Behav; 2004 Sep; 79(1):101-8. PubMed ID: 15388289
[TBL] [Abstract][Full Text] [Related]
20. Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.
Altarifi AA; Rice KC; Negus SS
Behav Pharmacol; 2013 Sep; 24(5-6):459-70. PubMed ID: 23881045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
